| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. A report from IQVIA found that biotech companies are becoming the most active group for later-stage pipeline work, while Big Pharma has seen its R&D share drop. In addition—out of last year’s strong harvest of 59 new FDA approvals—large pharmas filed fewer than half of the submissions, and emerging companies originated 64% of the drugs. However, Big Pharma is still spending big money on R&D, with the top 15 largest companies crossing the $100 billion mark for the first time last year—even while companies with more than $10 billion in annual sales saw their R&D share fall from 31% to 20% over the past decade. | |
|
Featured Story | | | Tuesday, April 23, 2019 The biotech industry is becoming the most active group for later-stage pipeline work, and while Big Pharma sees its R&D share drop, emerging life science companies are better prepared to go it alone. |
|
|
Top Stories Of The Week Wednesday, April 24, 2019 Move over, Johnson & Johnson—AbbVie just joined the party with a direct competitor to Tremfya, and analysts say it might just be best-in-class. Late Tuesday, the FDA greenlighted closely watched psoriasis prospect Skyrizi, the third member of Tremfya’s IL-23 class. Friday, April 19, 2019 A phase 3 trial has painted a mixed picture of the safety and efficacy of Eli Lilly and Pfizer’s painkiller tanezumab. Neither dose of the nerve growth factor inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments. Monday, April 22, 2019 On the cusp of Zolgensma's landmark FDA approval, Novartis has big hopes for the first-ever gene therapy for spinal muscular atrophy. But a patient’s death in the treatment's European trial could throw a wrench into its plans. Monday, April 22, 2019 The FDA has cleared the first medical device for treating attention deficit hyperactivity disorder: an at-home nerve stimulation system designed for children ages 7 to 12. Wednesday, April 24, 2019 Novartis is transforming Sandoz into an autonomous unit within the larger company. And it has tapped a former executive from the business—and an ex-GSK digital lead—to take the reins, fitting neatly into CEO Vas Narasimhan’s digital ambitions for the Big Pharma. Monday, April 22, 2019 Researchers led by the University of Southern California have designed a new type of CAR-T to reduce the risk of cytokine release syndrome, a side effect that can cause fever, brain swelling and other dangerous symptoms—and they have evidence from a small human study that they’re on the right track. Monday, April 22, 2019 The recall from the U.S. of tainted blood pressure medicines reached new heights as India’s Torrent Pharmaceuticals recalled 104 lots of losartan over the weekend because they contained an impurity suspected of causing cancer. Tuesday, April 23, 2019 Biotech and pharma companies shared their mid- to late-stage fatty liver disease data earlier this month at the EASL liver conference, and now the first-ever approval addressing this growing health burden appears to be peeking over the horizon. Tuesday, April 23, 2019 Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first—and some new phase 3 data could help make that happen. Taltz nailed its endpoints in a spondyloarthritis trial, Lilly said, paving the way for a potential FDA approval. Resources Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
